Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMAZING NEUROPEPTIDE
“Vasoactive intestinal peptide (VIP), a gut peptide hormone originally reported as a vasodilator in 1970, has multiple physiological and pathological effects on development, growth, and the control of neuronal, epithelial, and endocrine cell functions that in turn regulate ion secretion, nutrient absorption, gut motility, glycemic control, carcinogenesis, immune responses, and circadian rhythms.”
https://jayccampbell.com/peptides/vasoactive-intestinal-peptide/amp/
BILL B, IT IS LIKELY ALSO IN A DUSTY FILE BOX, SITTING IN A WAREHOUSE
“This drug was literally in 70 dusty file boxes, sitting in a warehouse,” Javitt said. “It had been developed in the 2000s for a number of lung diseases by a major pharmaceutical company. Then the company decided it would no longer focus on treatments for the lung, so the whole project was shelved where it remained until March 1, 2020, when we picked it up.”
https://www.phillymag.com/healthcare-news/2020/11/18/neurorx-respiratory-failure-covid-19/
NATURAL KILLER CELLS (NK)
AMAZING NEUROPEPTIDE
Vasoactive intestinal peptide (VIP) has recently been shown to bind to human lymphocytes and modulate immune functions. The ability of VIP in restoring natural killer (NK) cell activity depressed by hepatitis B surface antigen (HBsAg) has been investigated in the present research.
https://pubmed.ncbi.nlm.nih.gov/1418317/
The global hepatitis therapeutics market size was estimated at USD 21.9 billion in 2019 and is expected to reach USD 22.5 billion in 2020.
https://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics-market
It is known that VIP has various effects on intestinal functions: i) it is a potent stimulant of mucosal water and electrolyte secretion: ii) it is involved in the peristaltic reflex: and iii) plays an inhibitory role on immune cell function. Based on these biological effects it has been hypothesized that the intestinal mucosal immune system and inflammation may be influenced by alterations in the tissue concentrations of VIP. Some authors have demonstrated no changes in the VIP colonic content of patients with ulcerative colitis [UC], whereas others have demonstrated a reduction. Our results, using specific radioimmunoassay, showed that there is a significant decrease of VIP in both rectal and colonic mucosa of patients with ulcerative colitis [UC] as compared to controls. The VIP decrease is selective since substance P and calcitonin gene-related peptide were unchanged in the mucosal tissue of ulcerative colitis patients and furthermore the VIP alteration is correlated to the degree of mucosal inflammation. These findings suggest that the reduction of VIP mucosal content, even if it represents a non-specific event, could influence local inflammatory response and the activity of the disease.
https://www.sciencedirect.com/science/article/abs/pii/092842579390037T
The treatment of UC includes traditional therapies such as drugs made of tumor necrosis factor (TNF) inhibitors and small molecule. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.
https://www.alliedmarketresearch.com/ulcerative-colitis-market
So there is nothing to worry about.
And a lot to look forward to : today Ram has added a Chief Operations Officer. This is almost certainly linked to NRx Pharmaceuticals' statement about filing for the EUA by Monday. When you add APR, Advita Lifescience, the EU Pharmaceuticals and everything we are involved in, I personally absolutely love this appointment because it confirms our management know what it takes to get to the next step and is not hesitating doing it.
For me it is all looking good : I topped up on an almost daily basis when we were in the 0.17 - 0.18, like many on here who were able to at the time, and it is all packed away in the safe now. Yes, every single one of us were looking for the COVID play, but when you are small everything takes longer, regardless of how good your product may be, I know that from experience. But I would remind anyone doubting of three critical points :
1. ARDS, Sarcoidosis, Severe Asthma, and more, are all in play for us. That, eventually, is an even bigger play than COVID.
2. COVID is still a play until mid-2022.
3. Last but not least, look at all the institutional investors who have kept adding to their millions of shares since February. Even Credit Suisse - they sold some for liquidity after the Archegos disaster, and then a few weeks later bought close to ten times what they sold post Archegos.
So, two words - DON'T SELL !
>>>>> IIkas from y@h00 finance conversations
Who is directing the ducklings to the elevator??? Where is the baby Huey of ducklings (COPD/asthma)?
To develop potential therapies for Parkinson’s disease, inflammatory processes, mitochondrial dynamics, oxidative stress, production of reactive aldehydes, excitotoxicity and synucleinopathies are to be targeted. In this respect, vasoactive intestinal peptide has beneficial effects that provide an advantage for the treatment of Parkinson’s disease. Vasoactive intestinal peptide is a major neuropeptide-neurotransmitter having antioxidant, anti-inflammatory, neurotropic, neuromodulator, and anti-apoptotic properties. In addition to its direct neuroprotective actions regulating the activity of astrocytes, microglia and brain mast cells, it also plays important roles for neuronal adaptation, maintenance and survival.
https://www.eurekaselect.com/168911/article
The Parkinson's disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022. The carbidopa/levodopa drug class is projected to register highest CAGR during forecast period.
https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html
Fact checkers, Chinese checkers, what’s the difference???
https://epochtimes.today/facebook-fact-checker-funded-by-chinese-money-through-tiktok/
IS THE INDIAN VARIANT IN THE US???
Yes, the U.S. is one of 49 counties where the variant has spread, but so far it is at low levels here. As of May 8, the B.1.167 variant made up 3% of all COVID-19 cases in the United States, according to the Centers for Disease Control and Prevention.
COVID-19??? NO PROBLEM, THIS WILL BE A BREEZE, YES???
IF THE PERSONNEL GETS OVERWHELMED, TAKE IT EASY, PLAY SOME CHINESE CHECKERS, ITS JUST COVID-19, YES???
NO BIG DEAL, ITS COVID-19!!!
I WONDER WHAT WAS THE PANIC ABOUT??? IT WAS JUST COVID-19!!!
I TRUST IVES SAGOT PICK FOR RLFTF FLIGHT DIRECTOR/CREW, 1st STAGE OF A TIMELESS FLIGHT!!
Early in the Covid-19 pandemic, a research and development (R&D) consultant at Swiss pharma company Relief Therapeutics, Yves Sagot, realised that a drug developed in the early 2000s for acute respiratory distress and other lung diseases and acquired by Biogen could be effective at treating Covid-19. \\\\.
Relief then reached out to US-based NeuroRx to help them co-develop this drug for Covid-19, because the latter has a “history of taking already known molecules and moving them very quickly through the FDA”, explains NeuroRx CEO and chairman Professor Jonathan Javitt.
https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/
We’ve packed our bags, pre-flight! Waiting for liftoff, we are rocket men (generic)!!
Relief Therapeutics (OTC:RLFTF) is set for an upcoming boom. The company is developing a therapeutic drug for COVID-19 lung injury and I think that this stock is undervalued.
https://woodlandreport.com/2021/05/undervalued-relief-therapeutics-rlftf-is-gaining-traction/
When a Twitter user tipped us off last week to the mysterious disappearance of a preprint of a paper on a potential new therapy to treat Covid-19, we were curious. Was it a hidden retraction, or something else?
https://retractionwatch.com/2021/05/17/preprints-are-works-in-progress-the-tale-of-a-disappearing-covid-19-paper/
DR. BRYAN ARDIS | HOW COVID-19 HOSPITAL PROTOCOLS ARE LITERALLY KILLING PEOPLE INCLUDING HIS OWN FATHER-IN-LAW
CDC website directs patients and doctors to NIH Website for a protocol for treating COVID Patients.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
scroll down to “clinical management and treatment” and also “severe disease”, will be click link directing you to NIH guidelines.
NIH issues Protocol to Hospitals, how to treat COVID patients.
https://www.covid19treatmentguidelines.nih.gov/whats-new/.
Read Remdesivir protocol on NIH site Remdesivir is an INVESTIGATIONAL DRUG and is NOT FDA APPROVED FOR ANYTHING.
Do you know what the side effects of this NIH recommended investigational drug, which is also confirmed to NOT be FDA approved yet.
https://www.drugs.com/sfx/remdesivir-side-effects.html
read the 3 summaries under the warning section, 3 chinese produced findings from clinical experiences in CHINA on COVID patients.
I quote:
A cohort of 53 hospitalized patients in manufacturer’s compassionate-use program: Adverse effects (e.g., increased hepatic enzymes, diarrhea, rash, renal impairment, hypotension) reported in 60% of patients; serious adverse effects (e.g., multiple organ dysfunction syndromes, septic shock, acute kidney injury, hypotension) reported in 23%; drug discontinued because of adverse effects in 8% of patients.
https://www.thrivetimeshow.com/business-podcasts/dr-bryan-ardis-how-covid-19-hospital-protocols-are-literally-killing-people-including-his-own-father-in-law/.
WHO IS ASKING FOR SPECIAL TREATMENT, BILLIONAIRES???
You can’t sue Pfizer or Moderna if you have severe Covid vaccine side effects. The government likely won't compensate you for damages either
https://www.cnbc.com/2020/12/16/covid-vaccine-side-effects-compensation-lawsuit.html
FDA, ARE YOU GIVING AVIPTADIL EUA AND APPROVAL,...YESTERDAY???
Leukocyte trafficking is fundamental for immune responses and inflammation, as well as for the development of secondary immune tissues. Chemokines are key mediators of leukocyte chemotaxis to inflammatory sites in ailments including infectious diseases (1), asthma (2), rheumatoid arthritis (3), and inflammatory bowel disease (4, 5), and diseases hitherto thought noninflammatory, such as atherosclerosis (6).The key role of chemokines and their receptors in disease is highlighted by their subversion by pathogens such as herpesviruses, poxviruses, and HIV (7). Factors that mitigate chemokine functions are therefore desirable as therapeutic agents. Gene deletion animals and inhibition studies of specific chemokine receptors, however, suggest significant overlap in function. Thus, novel therapeutic strategies are required to target a number of receptors simultaneously to abrogate leukocyte recruitment and activation pathways.
https://www.jimmunol.org/content/171/10/4990
AND RAM, HAVE YOU PAID THE $4 MILLION TO NEURO RX OR DO YOU CARE AT ALL ABOUT THE USA THERAPEUTICS MARKET??? WHY MAKE BILLIONS WHEN WE CAN MAKE, MILLIONS???
https://www.marketdataforecast.com/market-reports/north-america-cancer-immunotherapy-market
CAN VIP HELP???
A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth
https://pubmed.ncbi.nlm.nih.gov/8389448/
WHAT CANCER IMMUNOTHERAPY COMPANIES ARE PAYING ATTENTION???
As cancer immunothrerapy has become more and more popular in research, a lot of companies have focused on this area to seek for ways for cancer treatments. 10 most famous cancer immunotherapy companies are listed here:
https://www.sinobiological.com/research/immunotherapy/cancer-immunotherapy-companies
WHO ELSE IS TAKING NOTE???
Pegylated interferon (Peg-IFN) in combination with ribavirin is the standard of care in the treatment of chronic hepatitis C (HCV). Peg-IFN is known to have a number of side effects but severe respiratory complications are uncommon. We report two cases, one of Peg-IFN induced interstitial pneumonitis (IP) and the other of bronchiolitis obliterans organising pneumonia (BOOP) in patients with chronic hepatitis C infection. In general, respiratory complications of Peg-IFN are mild and resolve with withdrawal of Peg-IFN. However, as illustrated in our first case fatal interstitial pneumonitis can occur.
https://pubmed.ncbi.nlm.nih.gov/23813142/
Checkpoint inhibitor-induced pneumonitis (CIP) is characterized clinically by dyspnea, cough and tachypnea. Hypoxia results from a lymphocyte-dominated alveolitis leading to ground glass opacities and consolidations observed by CT scan. Histological findings include lymphocytic infiltrates, granuloma formation and eosinophilic accumulation. In the management of CIP, systemic administration of steroids such as methylprednisolone is the standard therapy. Moreover, CIP in most cases leads to discontinuation of checkpoint inhibitory therapy and steroids limit the therapeutic effect of checkpoint inhibitors resulting in progression of the underlying malignant disease. Therefore, there is a need of other therapeutic options in CIP that ideally could abrogate the alveolar inflammation induced by checkpoint inhibitors without affecting the systemic effect on the immune system. The focus of the present invention is to deliver a solution to that problem by the topic application of VIP (vasoactive intestinal peptide, a peptide of 28 amino acids). A drug for inhalative VIP therapy is commercially available under the name Aviptadil.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020225246
SHOULD NEURORX PURSUE ANOTHER LUNG-RELATED CLINICAL TRIAL???
[immune checkpoint inhibitor]-pneumonitis in a real-world lung cancer cohort is more common and severe than previously reported.
https://www.cancertherapyadvisor.com/home/cancer-topics/lung-cancer/pneumonitis-lung-cancer-immune-checkpoint-clinical-trial-treatment/
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
https://pubmed.ncbi.nlm.nih.gov/31310589/
INTESTINAL PEPTIDE HEALS LUNG
https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
In the beginning, NeuroRX listened to Ives Sagot from Relief Therapeutics.
https://www.pharmasalmanac.com/articles/how-an-agile-company-addressed-the-pandemic-moving-from-psychiatric-medicines-to-a-covid-19-therapeutic
Seems Ives Sagot knew what entity was best equipped to move known molecules through the FDA. Should we ask Ives Sagot, why Neuro RX???
https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/
AGAIN, WHAT ENTITY KNOWS HOW TO MOVE A KNOWN MOLECULE THROUGH THE FDA??? Relief noted in today's press release that it was well aware of the stability issues related to aviptadil when the collaboration agreement was signed and committed to paying the costs of remediating those issues. When the merger agreement was signed with BRPA and the S-4 was filed, NeuroRx noted that the stability data provided by Relief had not yet been validated or replicated and identified this as a potential risk factor for investors. Solving stability challenges is a common feature of late-stage drug development programs, particularly with peptides such as aviptadil. NeuroRx's formulation, manufacturing, and GMP quality team is led by veteran executives who have piloted similar projects at leading pharmaceutical companies. Relief's nonpayment of those remedial formulation and manufacturing costs has not impeded NeuroRx's progress to delivering a lifesaving drug to patients in any way. Indeed, NeuroRx is actively collaborating with NIH to provide remediated formulation and stability data to European and South American Regulatory Authorities so that NIH can extend its recently-announced TESICO trial to Europe. https://www.prnewswire.com/news-releases/neurorx-responds-to-issues-raised-by-relief-therapeutics-regarding-zyesami-development-301271869.html
DO WE WANT PARITY WITH THE COVID 19 VACCINE???
https://www.globenewswire.com/news-release/2021/04/14/2209727/0/en/Global-Covid-19-vaccine-market-size-to-be-worth-USD-25-billion-by-2024.html
Top U.S. infectious-disease expert Anthony S. Fauci said Wednesday that the world has failed so far in tackling the global nature of the pandemic with a suitably global response, leading to tragedies like the current coronavirus outbreak in India. —————————————-
The nation of more than 1.3 billion is in the grip of a devastating surge, with more than 360,000 new cases in the past 24 hours — another global record — and 3,293 deaths, raising the toll past 200,000. Hospitals and crematoriums have been overwhelmed, and global assistance is only now slowly trickling in. ~ Washington Post
Standard of care, coming up!!!
Best
VIRAFIN, AVIPTADIL MAY HELP WITH iMMUNOTHERAPY-INDUCED PNEUMONITIS, AMONG OTHER HEALTH CONCERNS
Pegylated interferon (Peg-IFN) in combination with ribavirin is the standard of care in the treatment of chronic hepatitis C (HCV). Peg-IFN is known to have a number of side effects but severe respiratory complications are uncommon. We report two cases, one of Peg-IFN induced interstitial pneumonitis (IP) and the other of bronchiolitis obliterans organising pneumonia (BOOP) in patients with chronic hepatitis C infection. In general, respiratory complications of Peg-IFN are mild and resolve with withdrawal of Peg-IFN. However, as illustrated in our first case fatal interstitial pneumonitis can occur.
https://pubmed.ncbi.nlm.nih.gov/23813142/
Checkpoint inhibitor-induced pneumonitis (CIP) is characterized clinically by dyspnea, cough and tachypnea. Hypoxia results from a lymphocyte-dominated alveolitis leading to ground glass opacities and consolidations observed by CT scan. Histological findings include lymphocytic infiltrates, granuloma formation and eosinophilic accumulation. In the management of CIP, systemic administration of steroids such as methylprednisolone is the standard therapy. Moreover, CIP in most cases leads to discontinuation of checkpoint inhibitory therapy and steroids limit the therapeutic effect of checkpoint inhibitors resulting in progression of the underlying malignant disease. Therefore, there is a need of other therapeutic options in CIP that ideally could abrogate the alveolar inflammation induced by checkpoint inhibitors without affecting the systemic effect on the immune system. The focus of the present invention is to deliver a solution to that problem by the topic application of VIP (vasoactive intestinal peptide, a peptide of 28 amino acids). A drug for inhalative VIP therapy is commercially available under the name Aviptadil.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020225246
Along with other treatments, ZYESAMI will bring normalcy back to the whole world as a main player during the next 18-24 months. It will be in every household in the western and Eastern world but also in the emerging countries. These emerging countries will be very important because Zyesami will be affordable even for the poorest countries. But it will also be a new Big Drug for all kind of lung issues. The patent is good for several more years from this year on. And of course This will be at a few dollars only days after first approval. And weeks after we will be listed on the main exchanges. It's as easy as that. No need for RS and two digits latest when the inhaler is on the market. And have a look in 24 month. My guess? Three digits.
After markets crashes that may come, stocks like us will be a save harbor for a huge number of investors. So I think we are fine.
GLTA traders, HANS at y@h00 RLFTF conversations
NEURORX CARES ONLY ABOUT ZYESAMI APPLICATION TO COVID 19???
NeuroRx and TFF Pharmaceuticals believe the ability to deliver VIP directly to the lung via inhalation through the dry powder formulation of Zyesami could have important therapeutic implications and potentially expand the application of the drug to patients who are less severely affected by COVID-19.
https://www.drugdeliverybusiness.com/neurorx-tff-pharmaceuticals-enter-feasibility-agreement-for-zyesami-dry-powder-for-covid-19/
ITS A SMALL WORLD AFTER ALL
Jan 5, 2021 — The United States was the largest pharmaceutical market in 2019, generating roughly 45 percent of total revenues worldwide.
https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-pharmaceutical-markets/
CONFIDENCE IS HIGH???
For drugs that make it all the way through development, testing, and regulatory acceptance, the pharmaceutical company then gives the drug a trade name, which is a standard term in the pharmaceutical industry for a brand name or trademark name. ~ WIKI
The average cost of phase 1, 2, and 3 clinical trials across therapeutic areas is around $4, 13, and 20 million respectively. Pivotal (phase 3) studies for new drugs approved by the Food and Drug Administration (FDA) of the United States cost a median of $41,117 per patient.
https://www.sofpromed.com/how-much-does-a-clinical-trial-cost/
A study published by the Tufts Center for the Study of Drug Development published in the Journal of Health Economics in May 2019, gave an estimated cost of $2.6 billion. That study broke down the number to include approximate average out-of-pocket costs of $1.4 billion and time costs of $1.2 billion.
https://www.biospace.com/article/median-cost-of-bringing-a-new-drug-to-market-985-million/
RAM, IF YOU WANT OFF-PANDEMIC TRIAL PRICES, WHY NOT WAIT UNTIL THE PANDEMIC IS OVER??? RAM, DO INVESTORS A FAVOR, CALL NEURO RX AND TELL THEM THE $4 M CHECK IS IN THE MAIL!!!
In the beginning, NeuroRX listened to Ives Sagot from Relief Therapeutics.
https://www.pharmasalmanac.com/articles/how-an-agile-company-addressed-the-pandemic-moving-from-psychiatric-medicines-to-a-covid-19-therapeutic
Seems Ives Sagot knew what entity was best equipped to move known molecules through the FDA.
https://www.pharmaceutical-technology.com/features/neurorx-covid-19-respiratory-failure/
AGAIN, WHAT ENTITY KNOWS HOW TO MOVE A KNOWN MOLECULE THROUGH THE FDA???
Relief noted in today's press release that it was well aware of the stability issues related to aviptadil when the collaboration agreement was signed and committed to paying the costs of remediating those issues. When the merger agreement was signed with BRPA and the S-4 was filed, NeuroRx noted that the stability data provided by Relief had not yet been validated or replicated and identified this as a potential risk factor for investors. Solving stability challenges is a common feature of late-stage drug development programs, particularly with peptides such as aviptadil. NeuroRx's formulation, manufacturing, and GMP quality team is led by veteran executives who have piloted similar projects at leading pharmaceutical companies. Relief's nonpayment of those remedial formulation and manufacturing costs has not impeded NeuroRx's progress to delivering a lifesaving drug to patients in any way. Indeed, NeuroRx is actively collaborating with NIH to provide remediated formulation and stability data to European and South American Regulatory Authorities so that NIH can extend its recently-announced TESICO trial to Europe.
https://www.prnewswire.com/news-releases/neurorx-responds-to-issues-raised-by-relief-therapeutics-regarding-zyesami-development-301271869.html
AS I3ryant puts it, “Ram (chair of RLFTF), pay the 4 million expense and let’s move on”...let’s move that known molecule through the FDA!!!
Thank you!
Don't you think NRX wants to be listed and public before it announces great news? ~ William, Yah00 finance RLFTF conversations
NIH HELPING???
Regardless of evidence, the Chinese government and lab scientists continue to deny the possibility of SARS-CoV-2 leak from their lab. The U.S. intelligence agencies said they agree with a wide scientific consensus that the virus was not man-made or genetically modified, according to an April 30 statement by the Office of the Director of National Intelligence. Public and private researchers have said it is impossible to dismiss the possibility of an accidental leak from the Wuhan laboratory of what became the COVID-19 strain. Wuhan lab also received multiple grants for these bat-virus studies and for collecting these bats from the wild in the past. One of the grants was given to Wuhan lab from the U.S National Institute of Health (NIH), a government agency who awarded the Chinese facility with $ 3.7 million in 2014 and then with another $ 3.7 million in 2019, a total of $7.4 million was granted on the study of bat coronaviruses. The experiment lasted for 5 years and ended in 2019. In 2015, the director and the head supervisor of this study was Dr. Anthony Fauci (niaid.nih.gov). He became the director of National Institute of Allergy and Infectious Diseases (NIAID) in 1984 and continues to hold this position in 2020.
https://neiuindependent.org/17104/arts-life/opinion-what-they-forgot-to-tell-us-about-previous-coronaviruses/
There are ways to drastically improve preparedness for hundreds of thousands of Americans...
BUT
The U.S. government appears uninterested in major changes to its National Pandemic Plan.
https://threesecondsuntilmidnight.com/
In the sorry aftermath of the anthrax investigation, it’s clear that the National Institutes of Health and the Centers for Disease Control and Prevention have to rethink the priority-pathogens list, which includes anthrax, smallpox, plague, tularemia, Ebola and other germs that rarely, if ever, threaten American lives. It’s the “non-defense-related” germs that are killing us. Randall Wolcott of the Southwest Regional Wound Care Center points out that 500,000 Americans a year die of biofilm infections -- such as diabetic ulcers -- that are almost impossible to treat by conventional means. That’s almost twice as many as die of cancer.
https://www.latimes.com/archives/la-xpm-2008-aug-13-oe-orent13-story.html?_amp=true
The bidirectional connection between the nervous and the immune systems and the role it plays in wound healing has emerged as one of the focal features of the wound healing dogma. The mediators of this connection include neuropeptides and the cytokines released from different cells including immune and cutaneous cells. Therefore, to develop successful wound healing therapies, it is vital to understand in depth the signaling pathways in the neuro-immune axis and their implication in diabetic wound healing.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708299/
The global diabetic foot ulcer treatment market size was valued at USD 3.6 billion in 2017. It is anticipated to expand at a CAGR of 8.2% over the forecast period. Rising prevalence of diabetes and rapidly growing geriatric population worldwide are among the primary growth stimulants for DFU treatment market. Diabetic foot ulcer is one of the major complications of diabetes mellitus, which forms a major characteristic of diabetic foot.
https://www.grandviewresearch.com/industry-analysis/diabetic-foot-ulcer-dfu-treatment-market
Thank you ratna1, will do! Qvo Vadis!!! Love it!
Hi Ratna1, yes I was able to read it, many thanks! I will keep this very much in mind when we go to her cardiologist appointment next Tuesday, thanks again!
Since immune checkpoint inhibitor (ICI) blockade has become standard therapy for many cancers, immune-related adverse events (irAEs) have increased. ICI-pneumonitis is infrequent but potentially fatal. In cases not responsive to corticosteroids, additional immunosuppression is recommended. Data for use of infliximab in ≥ grade 3 pneumonitis is sparse.
https://meridian.allenpress.com/innovationsjournals-JIPO/article/3/4/172/446353/Role-of-Infliximab-in-Immune-Checkpoint-Inhibitor
What if VIP becomes part of checkpoint-inhibitor treatment for cancers? —- The global adalimumab, infliximab, and etanercept market is expected to grow from $2.2 billion in 2019 to $2.27 billion in 2020 at a compound annual growth rate (CAGR) of 3.24%. The market is expected to recover and reach $7.50 billion in 2023 at a CAGR of 48.94%.
https://www.businesswire.com/news/home/20210204005555/en/Global-Adalimumab-Infliximab-and-Etanercept-Biosimilars-Market-Report-2020---ResearchAndMarkets.com
Pneumonitis (noo-moe-NIE-tis) is a general term that refers to inflammation of lung tissue. Technically, pneumonia is a type of pneumonitis because the infection causes inflammation. Pneumonitis, however, is usually used by doctors to refer to noninfectious causes of lung inflammation.
https://www.mayoclinic.org/diseases-conditions/pneumonitis/symptoms-causes/syc-20352623
I makes a lot of sense J-B, a whole lot of sense!! Thank you for emphasizing this!!
https://www.nejm.org/doi/full/10.1056/NEJMc2000343
The size of the global checkpoint inhibitors market was valued at USD 12.9 billion in 2020. Is expected to worth USD 45.4 billion by 2025, growing at a CAGR of 28.68% between 2020 to 2025.
https://www.marketdataforecast.com/market-reports/global-checkpoint-inhibitors-market